Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Study Information
Alliance Study ID: CALGB-19807
NCT Study ID (ClinicalTrials.gov): NCT00004933
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: Dan DeAngelo, MD
Status: TERMINATED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia that has not responded to interferon alfa.
PURPOSE: Randomized phase III trial to compare the effectiveness of homoharringtonine with that of hydroxyurea in treating patients who have chronic myelogenous leukemia that has not responded to interferon alfa.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information